Avelumab and Pepinemab

Phase 2

Vaccinex, Inc. (VCNX)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Metastatic Pancreatic Adenocarcinoma

Clinical Trial

NCT05102721

Last updated: 12/4/2025

Regulatory Approvals

EMA9/18/2017

Bavencio

Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first?line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum?based chemotherapy.

View on EMA

Developer

VCNX

Vaccinex, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

VX15/2503 + avelumabPhase 2

Carcinoma, Non-Small-Cell Lung

pepinemab + pembrolizumabPhase 2

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

VX15/2503Phase 2

Huntington's Disease

PepinemabPhase 2

Alzheimer Disease

View full pipeline